HomeAI · summaries
Storia in 2 fonti
Bernstein starts Summit with an Underperform, says ‘not on solid footing’
Bernstein analyst Jeffrey Walch initiated coverage of Summit Therapeutics (SMMT) with an Underperform rating and $7.70 price target The firm re...
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
markets.businessinsider.com
Bernstein starts Summit with an Underperform, says ‘not on solid footing’
Bernstein analyst Jeffrey Walch initiated coverage of Summit Therapeutics (SMMT) with an Underperform rating and $7.70 price target The firm re...
- ·
benzinga.com
This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday - Centene (NY
Analysts changed outlook on top names, including SMMT, DAVA. See what others think before buying SMMT stock.